How Long Does Dysport Last? What Must Hold First

For FDA-labeled treatment of frown lines between the eyebrows, Dysport may last up to four months, according to the Dysport U.S. Prescribing Information, and retreatment should occur no more often than every three months. That answer applies to 50 Dysport Units placed across five sites in the corrugator and procerus muscles and assessed as glabellar-line severity at maximum frown; it does not automatically apply to the forehead, crow’s feet, a lip flip, another dose plan, or BOTOX Cosmetic Units.

When does the “up to four months” answer apply?

The four-month figure describes a specific treatment and a specific way of measuring it. Dysport is FDA-approved for the temporary improvement of moderate to severe glabellar lines associated with corrugator and procerus activity in adults younger than 65. Those are the vertical frown lines between the brows, assessed while the person frowns as hard as instructed.

The current Dysport U.S. Prescribing Information gives six anchors worth keeping together:

| Question | Verifiable figure | What the figure actually describes | | --- | ---: | --- | | What is the labeled glabellar dose? | 50 Units | Five intramuscular injections of 10 Units: two in each corrugator and one in the procerus | | How long were single-dose trials followed? | 180 days in GL-1; 150 days in GL-3 | Follow-up length, rather than a promise that every response persisted that long | | What happened on Day 30? | 55% in GL-1; 52% in GL-2; 60% in GL-3 | Participants reached the label’s composite treatment-success threshold | | How long was line severity reduced? | Up to 4 months | Glabellar-line severity at maximum frown | | What is the retreatment limit? | No more frequently than every 3 months | A minimum three-month interval between labeled glabellar treatments | | How often did adverse reactions occur in pooled placebo-controlled trials? | 48% with Dysport; 33% with placebo | Reactions of any cause in the Dysport N=398 and placebo N=496 columns; some participants appear in both |

“Responder” needs its definition. In the Dysport trials, both the investigator and the participant used a four-point scale: none, mild, moderate, or severe. Day 30 success required a rating of none or mild, at least two grades better than baseline, on the combined assessments. GL-3 followed 300 previously untreated participants for 150 days; 120 of 200 Dysport recipients, or 60%, met that Day 30 composite endpoint. None of the 100 placebo recipients did.

The adverse-reaction total counts events from any cause, so it does not mean Dysport caused every report. The label’s pooled columns were Dysport N=398 and placebo N=496; some participants appeared in both. Headache occurred in 9% with Dysport versus 5% with placebo, injection-site pain in 3% versus 2%, and eyelid ptosis in 2% versus less than 1%. These pooled rates do not predict an individual response.

Why do some Dysport materials say five months?

The official Dysport patient website says results “may last up to 5 months.” Its footnote ties that statement to a post-hoc analysis of GL-1 and GL-3, using at least a one-grade improvement from baseline on the Glabellar Line Severity Scale; those studies observed participants for at least 150 days. The prescribing information uses the more restrained wording that treatment reduced glabellar-line severity for up to four months.

The difference is the analytical threshold. A one-grade improvement at a late visit asks whether any defined improvement remains. The pivotal Day 30 composite asks whether both observer and participant found the line none or mild with at least a two-grade gain. Moving from severe to moderate may count under the first threshold while failing the second.

For planning, I prefer the label’s up-to-four-month answer. Treat five months as a possible outer result, not a date for every calendar. If a clinic quotes it, ask which area, dose, baseline grade, expression, and response threshold support the estimate.

Which treatment details shape visible duration?

Duration starts with the muscle map. The labeled Dysport pattern treats two corrugator muscles, which pull the brows inward and down, and the procerus, which contributes to the central frown. It does not treat the frontalis across the forehead, the orbicularis oculi around the eyes, or the orbicularis oris used in a lip flip.

The four-month glabellar figure cannot answer a search for “Dysport on forehead duration.” Dysport around the eyes and a Dysport lip flip are off-label cosmetic uses in the United States; the label supplies no duration for either. An injector may rely on clinical experience, but the estimate should be identified as practice-based.

Baseline matters too. The pivotal studies enrolled people whose lines were at least moderate at maximum frown and excluded people with marked ptosis, deep dermal scarring, or a substantial inability to soften the line by physically spreading it apart. A deeply etched line visible at rest can remain even when the underlying muscle has weakened. If “lasting” means perfectly smooth skin at rest, that is a different endpoint from the trial’s line-severity score at maximum frown.

The dose has meaning only inside its own product. Fifty Dysport Units cannot be converted into BOTOX Cosmetic Units because each manufacturer’s potency assay defines its Units. The Dysport and BOTOX Cosmetic prescribing information both state that their Units cannot be compared or converted to those of another botulinum toxin product. A ratio copied from social media cannot repair that incompatibility.

Handling is another condition behind the trial result. The Dysport specification calls for reconstitution with preservative-free 0.9% Sodium Chloride Injection using aseptic technique. The solution should be clear, colorless, and particle-free. Once reconstituted, it remains in the original container, protected from light at 36°F to 46°F, must be used within 24 hours, and must not be frozen. A patient can ask which product was used and whether the record identifies the dose and areas.

What should you record so a follow-up is clinically useful?

A useful record lets the injector compare the same face, expression, angle, and elapsed time. Random selfies usually change all four. Until about 2022, I advised patients to keep daily photos when they felt a treatment was fading. I stopped because the volume created false alarms: camera distance, brow effort, and lighting varied more than the line. Fewer standardized images produced clearer portal reviews.

Keep one compact treatment record

Write down the treatment date, exact product name, total Units, Units by area if provided, treated areas, injector and clinic, and planned assessment date. Include other botulinum toxin products received in the previous four months, medication changes, prior facial surgery, and any earlier reaction your prescriber asked about. The Dysport Medication Guide specifically tells patients to identify which toxin product they received and to report other botulinum toxin use.

Define the goal in observable terms before judging duration. “Soften the 11s at full frown while preserving some brow movement” can be reviewed. “Make me look refreshed” cannot. Record the baseline line at rest and at maximum frown as none, mild, moderate, or severe, mirroring the label’s scale. At the planned assessment, repeat that maximum-frown view and grade. Movement can return before an etched line looks as it did at baseline, so record each separately. A review on another day should not be relabeled as the trial’s Day 30 endpoint.

Take photos at fixed checkpoints

1. Before treatment, photograph the face at rest and at maximum frown. Add maximum eyebrow elevation or a full smile only if those areas were treated.
2. Repeat the same views after onset, at the clinic’s planned assessment, on Day 30, and then monthly until the agreed endpoint returns. The official Dysport site reports a median onset of two days in GL-3 and three days in GL-1 and GL-2, based on subject self-assessment; onset is earlier than final judgment.
3. Use the same camera, lens setting, distance, head position, expression cue, and lighting direction. Avoid beauty mode and mirrored-image switching.
4. Note the first date movement changed, the date the result felt settled, and the date your chosen endpoint returned. Log headache, eyelid change, dry-eye symptoms, pain, or other new symptoms with start and stop dates.

The strongest objection to this method is fair: scheduled photos can turn an elective treatment into daily facial surveillance. That happens. Four purposeful checkpoints and monthly follow-up are enough for most records; a camera roll full of repeated frowns often makes tiny normal differences feel urgent.

What should you do if Dysport fades early or looks uneven?

Document before seeking more toxin. Take matching photos at rest and during the same expression, then send the treatment date, product, dose if known, areas treated, date you first noticed the change, and any symptoms. Say whether one side has more movement, one brow or lid changed position, the original line returned evenly, or a line at rest never changed. Those are different follow-up questions.

Use the clinic’s planned assessment as an assessment, not an automatic injection appointment. Early asymmetry can change as onset develops, while the Dysport label says retreatment for glabellar lines should occur no more frequently than every three months. Another injector cannot safely interpret an isolated Unit count as if Dysport and BOTOX Cosmetic shared a conversion scale. Bring the full record if you seek a second opinion.

I once treated an unanswered portal thread as resolved because the screen said “closed.” It cost the patient another message and cost me my trust in status labels. A portal status still does not prove a clinician reviewed your concern. If you receive no substantive reply, call the clinic and state what changed and when.

Some symptoms should bypass routine photo comparison. The FDA-approved boxed warning says toxin effects can spread beyond the injection site hours to weeks later. Seek immediate medical care for trouble swallowing, speaking, or breathing, or generalized weakness. Report persistent eye pain, irritation, light sensitivity, or vision changes to the treating clinician; the Dysport label warns about dry eye after glabellar treatment.

How does Dysport compare with BOTOX Cosmetic for frown lines?

The labels place both products in a similar duration window for glabellar lines, but they do not establish that one lasts longer. The comparison below uses the current U.S. prescribing information for each product.

| Label feature | Dysport | BOTOX Cosmetic | | --- | --- | --- | | Active ingredient | abobotulinumtoxinA | onabotulinumtoxinA | | Labeled glabellar dose | 50 product-specific Units | 20 product-specific Units | | Injection pattern | Five sites, 10 Units each | Five sites, 4 Units each | | Labeled muscles | Corrugators and procerus | Corrugators and procerus | | Duration wording | May last up to 4 months | Approximately 3 to 4 months | | Trial duration evidence | GL-1 followed 180 days; GL-3 followed 150 days | Severity reduction measured through Day 120 | | Day 30 result | 55%, 52%, and 60% composite two-grade success across GL-1, GL-2, and GL-3 | 80% investigator-rated none/mild; 89% subject-rated at least moderate improvement in two combined studies |

The percentages do not support a race between products. Dysport required a combined investigator-and-subject two-grade result for the quoted composite; BOTOX Cosmetic reported two separate co-primary responder definitions. The BOTOX Cosmetic studies included 405 treated participants and 132 placebo recipients, then reported 25% investigator responders and 39% subject responders at Day 120. Cross-trial percentages mix different definitions, populations, and study designs.

The clean comparison is narrower. Dysport’s label says up to four months, and BOTOX Cosmetic’s says approximately three to four months for glabellar lines. Neither label authorizes a Unit conversion. Your own consistently recorded cycles may be more useful for choosing between them than a clinic’s generic claim of superior longevity.

When does repeating Dysport remain a reasonable maintenance plan?

Repeat treatment remains reasonable when the benefit reaches a goal you defined, lasts long enough to justify treatment within the label’s three-month minimum interval, and does not ask you to accept an adverse effect you consider disproportionate. A person who values slight movement may choose a different endpoint from someone seeking none-or-mild severity at maximum frown.

Review the pattern rather than one disappointing cycle: product, muscles, dose, baseline line, expression at assessment, and any new medication, illness, surgery, or toxin exposure. The label says the effect of giving different botulinum toxins at the same time or within several months is unknown, and another administration before the previous effect resolves may worsen excessive weakness.

Repeated exposure has evidence, with limits. The Dysport prescribing information reports continued efficacy through as many as four repeated administrations. Antibody testing covered 1,554 glabellar-line participants treated for up to nine cycles; three developed binding antibodies after treatment, and none tested positive for neutralizing antibodies. That result does not guarantee lifelong response or settle every individual case.

I have never injected botulinum toxin, so I cannot personally vouch for a clinician’s placement or a patient’s biological response. I can vouch for what survives patient-portal moderation: a dated product record, comparable expressions, and a precise description get a more answerable follow-up than “it wore off.” If satisfactory benefit repeatedly disappears well before three months, the useful next question is whether the indication, muscle plan, product, and goal still fit. Compressing the interval on your own conflicts with the label.

Frequently asked questions

Does Dysport last longer than Botox?

No product label establishes that Dysport consistently lasts longer. Dysport’s U.S. prescribing information says glabellar-line effects may last up to four months; the BOTOX Cosmetic label says approximately three to four months. Their Units, populations, and responder definitions differ, so percentages from separate trials cannot rank durability. Compare standardized records from your own treatment cycles.

How many times a year should Dysport be repeated?

The Dysport label says glabellar-line retreatment should occur no more frequently than every three months. That usually works out to no more than four treatment sessions a year; it does not mean everyone needs four. Repeat only after your prescriber reassesses the prior benefit, adverse effects, current muscle pattern, and maintenance goal.

Why does Dysport wear off quickly?

Apparent early fading can reflect strong muscle recruitment, untreated neighboring muscles, an off-label area, a changed dose or placement plan, or confusion between returning movement and a static etched line. Inconsistent photo angles can also create false change. Document the product, dose, area, timeline, expressions, and symptoms, then ask the injector to assess the cause.

How long does Dysport take to work?

On the official Dysport patient site, median onset based on subject self-assessment was two days in GL-3 and three days in GL-1 and GL-2; some participants responded on Day 1. Onset is not the final assessment. Follow the clinic’s planned review date and contact the injector sooner if concerning symptoms appear.

How long does Dysport last around the eyes?

The U.S. Dysport indication and four-month label claim cover glabellar lines between the brows, not lateral canthal lines around the eyes. The label therefore supplies no Dysport around-eyes duration. If an injector treats that area off-label, ask for the exact muscle, product-specific dose, planned assessment, and evidence behind the estimate.

What outcome did the product trial measure?

In Dysport’s pivotal glabellar studies, investigators and participants rated maximum-frown severity on a four-point scale: none, mild, moderate, or severe. Overall Day 30 success required none or mild plus at least a two-grade improvement from baseline on their combined assessments. That endpoint is more specific than a general report of smoother-looking skin.